BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16121769)

  • 1. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
    Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
    Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug clinics. How I treat cutaneous melanoma].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considering adjuvant therapy for stage II melanoma.
    Poklepovic AS; Luke JJ
    Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous head and neck melanoma: the old and the new.
    Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in melanoma staging and therapy.
    McMasters KM; Sondak VK; Lotze MT; Ross MI
    Ann Surg Oncol; 1999; 6(5):467-75. PubMed ID: 10458685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic manual of malignant melanoma].
    Moroi Y
    Fukuoka Igaku Zasshi; 2009 Feb; 100(2):51-8. PubMed ID: 19455975
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
    Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
    Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations].
    Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ;
    Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 2):10S3-10S85. PubMed ID: 16521904
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant therapies for malignant melanoma.
    Olofsson Bagge R; Ny L
    Br J Surg; 2016 Aug; 103(9):1095-6. PubMed ID: 27246114
    [No Abstract]   [Full Text] [Related]  

  • 13. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
    Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
    Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of melanomas].
    Zimmer L; Vaubel J; Schadendorf D
    Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
    Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
    Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities.
    Otley CC; Zitelli JA
    Dermatol Surg; 2000 Mar; 26(3):177-80. PubMed ID: 10759789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current therapy of carcinoma of the skin].
    Dummer R; Goldinger SM; Sailer E; French LE
    Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.